Sinew Pharma Inc. (TPEX:6634)
54.70
+2.50 (4.79%)
May 8, 2026, 1:47 PM CST
Sinew Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 25.27 | 41.39 | 166.81 | 246.68 | 551.17 |
Short-Term Investments | 1,027 | 1,118 | 1,109 | 1,144 | 931.49 |
Cash & Short-Term Investments | 1,052 | 1,159 | 1,275 | 1,391 | 1,483 |
Cash Growth | -9.22% | -9.13% | -8.31% | -6.17% | 338.25% |
Accounts Receivable | 0.05 | - | - | - | - |
Other Receivables | 24.05 | 21.43 | 18.87 | 16.3 | 14.3 |
Receivables | 24.1 | 21.43 | 18.87 | 16.3 | 14.3 |
Prepaid Expenses | 1.16 | 0.78 | 0.52 | 0.63 | 4.22 |
Other Current Assets | - | - | 0.57 | - | - |
Total Current Assets | 1,077 | 1,181 | 1,295 | 1,408 | 1,501 |
Property, Plant & Equipment | 17.05 | 7.12 | 18.86 | 14.35 | 4.51 |
Other Intangible Assets | 15.44 | 22.27 | 38.51 | 55.58 | 67.23 |
Other Long-Term Assets | 17.69 | 15.46 | 10.55 | 9.15 | 11.84 |
Total Assets | 1,128 | 1,226 | 1,363 | 1,487 | 1,585 |
Accrued Expenses | 16.06 | 18.33 | 22.9 | 15.36 | 10.56 |
Current Portion of Leases | 5.97 | 2.82 | 6.46 | 2.99 | 1.05 |
Current Unearned Revenue | 0.52 | 0.52 | 0.52 | 0.52 | 0.85 |
Other Current Liabilities | 2.94 | 5.52 | 5.31 | 4.38 | 2.65 |
Total Current Liabilities | 25.49 | 27.18 | 35.19 | 23.25 | 15.11 |
Long-Term Leases | 9.23 | - | 2.82 | 4.56 | - |
Other Long-Term Liabilities | 1.7 | 1.7 | 1.7 | 0.85 | 0.85 |
Total Liabilities | 36.42 | 28.88 | 39.71 | 28.66 | 15.96 |
Common Stock | 712.89 | 713.15 | 711.66 | 697.72 | 690.09 |
Additional Paid-In Capital | 826.12 | 816.47 | 808.87 | 900.96 | 1,067 |
Retained Earnings | -445.04 | -321.29 | -170.92 | -140.18 | -188.43 |
Comprehensive Income & Other | -2.8 | -11.07 | -25.95 | - | 0.43 |
Shareholders' Equity | 1,091 | 1,197 | 1,324 | 1,459 | 1,569 |
Total Liabilities & Equity | 1,128 | 1,226 | 1,363 | 1,487 | 1,585 |
Total Debt | 15.21 | 2.82 | 9.28 | 7.55 | 1.05 |
Net Cash (Debt) | 1,037 | 1,156 | 1,266 | 1,384 | 1,482 |
Net Cash Growth | -10.32% | -8.68% | -8.48% | -6.61% | 342.31% |
Net Cash Per Share | 14.59 | 16.21 | 17.97 | 19.97 | 24.90 |
Filing Date Shares Outstanding | 71.29 | 71.31 | 71.17 | 69.77 | 69.01 |
Total Common Shares Outstanding | 71.29 | 71.31 | 71.17 | 69.77 | 69.01 |
Working Capital | 1,052 | 1,154 | 1,260 | 1,385 | 1,486 |
Book Value Per Share | 15.31 | 16.79 | 18.60 | 20.90 | 22.73 |
Tangible Book Value | 1,076 | 1,175 | 1,285 | 1,403 | 1,502 |
Tangible Book Value Per Share | 15.09 | 16.48 | 18.06 | 20.11 | 21.76 |
Machinery | 13.4 | 12.93 | 12.75 | 7.11 | 5.83 |
Leasehold Improvements | 11.28 | 11.28 | 11.28 | 9.31 | 4.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.